|Last Price||£29.13||Day Change||£0.34 (0.0117%)|
|Price Date||4 Dec 2023||Morningstar Rating|
|Shares Class||Inc||Yield||0.05 %|
|Last Ex-Dividend Date||01 January 2020||Dividend Frequency||-|
|Launch Date||01/01/2020||Standard Initial Charge||0.00%|
|Ongoing cost||0.87%||Annual Management Charge||0.00%|
The Fund’s investment objective is long-term growth of capital. It pursues its objective by investing at least 80% of its net asset value in equities (also known as company shares) located anywhere in the world and selected for their growth potential. The Fund will invest at least 80% of its net asset value in companies that the relevant Sub-Investment Adviser believes have a life sciences orientation. Generally speaking, the “life sciences” relate to maintaining or improving quality of life. Thus, companies with a “life sciences orientation” include companies engaged in research, development, production or distribution of products or services related to health and personal care, medicine or pharmaceuticals. Such companies may also include companies that the relevant Sub-Investment Adviser believes have growth potential mainly as a result of particular products, technology, patents or other market advantages in the life sciences.
Janus Henderson Investors
daily news email
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of directors' buys and sells
- Articles from Shares magazine